Bwayo J, Jackson D, Rakwar J, Nyange P, Martin H, Kreiss J; International Conference on AIDS.

Int Conf AIDS. 1994 Aug 7-12; 10: 339 (abstract no. PC0291).

Department of Medical Microbiology, University of Nairobi, Kenya.

OBJECTIVE: To assess the acceptability of phase III trials of candidate HIV vaccines in high risk male and female prospective cohorts in Mombasa. METHODS: A standardised questionnaire was administered to a sample of HIV seronegative male (m) trucking company employees (n = 67) and female (f) sex workers (n = 61) who were enrolled in existing HIV high risk cohort studies, as part of the Preparation for AIDS Vaccine Evaluation initiative. RESULTS: General knowledge about vaccines was tested, with 78% (75%f, 81%m) giving a correct definition of a vaccine, 91% (88%f, 93%m) able to name a vaccine preventable disease, 48% (48%f, 49%m) knowing that vaccines are not 100% efficacious, and 34% (33%f, 36%m) aware that vaccines could have side effects. While 93% (90%f, 96%m) thought that HIV was a major problem in Kenya, 12% (15%f, 9%m) felt at no personal risk of HIV infection. If offered a safe, efficacious HIV vaccine, 89% (89%f, 90%m) stated that they would accept. If offered participation in a randomized trial of a candidate HIV vaccine of unknown efficacy, 84% (87%f, 81%m) agreed to a double blind placebo controlled design, 80% (77%f, 82%m) agreed to participate even if the vaccine gave them a "false positive" HIV serologic result, and 84% (87%f, 81%m) agreed to a follow up period of 3 to 5 years. Two respondants (1f, 1m) said they would increase their number of sex partners if in a vaccine trial and 12% (3%f, 19%m) stated that they would decrease condom use. This gender difference in anticipated change in condom use was the only such difference which was statistically significant (p = 0.01). At the end of the questionnaire, 84% (85%f, 82%m) said they would participate in an HIV vaccine trial, as outlined. DISCUSSION: These results suggest that acceptance of an HIV vaccine trial would be high in these cohorts. That 19% of men stated that they would decrease condom use if in an HIV vaccine trial highlights the need for continuing education.

Publication Types:

• Meeting Abstracts

Keywords:

• AIDS Vaccines
• Acquired Immunodeficiency Syndrome
• Clinical Trials as Topic
• Clinical Trials, Phase III as Topic
• Cohort Studies
• Double-Blind Method
• Female
• HIV Infections
• HIV Seropositivity
• Humans
• Kenya
• Longitudinal Studies
• Male
• Prostitution
• epidemiology

Other ID:

• 94370288

UI: 102209118

From Meeting Abstracts